Twist Bioscience Stock: 6 Straight Green Days, Up 24%
A recent run has put the stock in the spotlight, but the underlying numbers present a divided picture.
Twist Bioscience (TWST) has now gained for 6 consecutive trading days. The cumulative gain over this 6-day streak is 23.9%, adding about $1.9 billion to the company’s market value. The stock now has a market value of about $9.7 billion.
Twist Bioscience stock trades at about $155.56 a share as of 9/17/2026.
The Streak Next To The S&P 500
Here is how TWST stock stacks up against the S&P 500 over the streak and the periods around it:
| Return Period | TWST | S&P 500 |
|---|---|---|
| 1D | 8.7% | 1.1% |
| 6D (Current Streak) | 23.9% | 0.0% |
| 1M (21D) | 34.0% | -0.7% |
| 3M (63D) | 87.7% | 2.9% |
| YTD 2026 | 390.4% | 11.6% |
| 2025 | -31.7% | 16.4% |
| 2024 | 26.1% | 23.3% |
| 2023 | 54.8% | 24.2% |
What do the numbers say about the business?
The recent move is the stock’s own story. Over the same 6 trading days the S&P 500 returned +0.02%.
The company’s financial profile presents a mixed picture across growth and profitability. Revenue over the last twelve months grew 19.2%, ahead of the 8.1% median. However, its operating margin over the last twelve months is -32.0%, against a median of 17.6%. The company also has negative trailing earnings.
A streak is a signal, not a strategy.
A run of consecutive gains or losses is information. It signals that the market’s attention and momentum are focused on a stock, for reasons that may or may not be clear.
It is not, by itself, an instruction to act. The disciplined response is to use the new price as a reason to re-evaluate the business. The stock’s return over the trailing twelve months is +474.4%, but it posted a loss of 31.7% in 2025, showing how performance can vary over time.
If you are hunting for strength that has more behind it than a hot tape, our Guidance Momentum screen surfaces the names where management raised its own outlook, which is the kind of momentum that tends to persist.
And for anyone who would rather back the theme than one company’s story, a biotech ETF like XBI holds the whole group, not the single stock. It is still a concentrated bet on that one theme, though, which is exactly the gap the portfolio below closes.
One Hot Stock Is A Story. Thirty Sound Ones Are A Strategy
A streak like this earns a place on your watchlist, and it also earns a question: how much of your outcome do you want depending on one company keeping this up?
The Trefis High Quality (HQ) Portfolio answers it with breadth: roughly 30 businesses picked for consistent cash generation, strong margins, and balance-sheet strength, sized and rebalanced by rules. It has a track record of outpacing a benchmark that combines the three major indices – the S&P 500, S&P Mid-cap, and Russell 2000. Follow the story; invest in the strategy.